Panacos Pharmaceuticals, Inc. (PANC) Reports Q3 In-Line
More News related to PANC
- Panacos Pharmaceuticals (PANC) Hires Oppenheimer & Co. to Review Strategic Alternatives; Reduces Workforce
- Panacos Pharmaceuticals (PANC) Reports Q3 Loss of $0.15, Beats by 5c
- Panacos Pharmaceuticals, Inc. (PANC) Reports Q3 In-Line
- Pre-Open Movers 6/18: Lindsay Corp (LNN) Lower After Results, Fifth Third (FITB) Sinks on Capital Raise/Div Cut/Revised Capital Ratio
- Panacos Pharmaceuticals (PANC) Reports Q1 Loss of $0.16, Tops Street By 3c
More News related to Earnings
- Highlights From LDK's Q3 Conference Call: Sales up 23% Over Prior Quarter; Guides Well Above for Q4
- Highlights From JOBS Q3 Conference Call: Shares Jump on Strong Earnings and Rebound in Market Demand
- Mercantile Bancorp (MBR) Posts Q3 Loss of $0.16, Wider than Views
- Campbell Soup (CPB) Q1 Earnings and Guidance are Mmm Mmm Good
- Natuzzi SpA (NTZ) Posts Q3 Loss of €0.02, Better Y/Y; Revs Lower
Panacos Pharmaceuticals, Inc. (Nasdaq: PANC) reports Q2 loss of $0.18, cents better than the analyst estimate of ($0.18). Revenues for the quarter were $18K, versus the consensus of $40K.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
